Abstracts tagged "Clinical practice"

Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium
Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Mei-Sing Ong¹, Gordon Schiff ² and Marc Natter ³ for the CARRA investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Harvard Medical School, Boston, ³Boston Children's Hospital, Boston
Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…
Abstract Number: 191 • 2020 Pediatric Rheumatology Symposium
Utilization of Telemedicine in Pediatric Rheumatologic Care
Rajdeep Pooni¹ and Tzielan Lee ¹, ¹Stanford Children's, Palo Alto
Background/Purpose: Telemedicine has the potential for improving access to care, particularly for pediatric patients with complex needs in remote or rural locations. Previous studies have…
Abstract Number: 302 • 2019 ACR/ARP Annual Meeting
Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center
Sarah Chung¹, Katherine Wysham ², Elizabeth Jernberg ³, Ingeborg Sacksen ³, Scott Pollock ¹ and Alison Bays ¹, ¹University of Washington Division of Rheumatology, Seattle, WA, ²Veterans Health Administration Puget Sound, Seattle WA, Seattle, ³University of Washington Division of Rheumatology, Seattle
Background/Purpose: Routine use of musculoskeletal ultrasound (MSK-US) to aid in clinical decision-making for rheumatology patients is less common in the United States than in Europe,…
Abstract Number: 654 • 2019 ACR/ARP Annual Meeting
Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease
Kyle Drehmel¹, Alan Erickson ¹, Bryant England ² and Michelene Hearth-Holmes ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha
Background/Purpose: Undifferentiated Connective Tissue Disease (UCTD) describes the clinical scenario where a patient demonstrates characteristics of a connective tissue disease but does not meet criteria…
Abstract Number: 1530 • 2019 ACR/ARP Annual Meeting
Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Uta Kiltz ¹, Elizabeth Holdsworth², Haijun Tian ³, Nicola Booth ⁴, Papa Anthony ⁵, Lina Helsche ⁶, Dorothy Keininger ⁶ and Philip G Conaghan ⁷, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Adelphi Real World, Manchester, England, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Adelphi Real World, Macclesfield, England, United Kingdom, ⁶Novartis Pharma AG, Basel, Basel-Landschaft, Switzerland, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life. Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.…
Abstract Number: 2461 • 2019 ACR/ARP Annual Meeting
Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement
Alfred Cividino¹, Denise Nicholson ², Sherif Guindi ², Jennifer Jelley ², Anne-Julie Gaudreau ² and Dafna Gladman ³, ¹McMaster University's Faculty of Health Sciences, Hamilton, ON, Canada, ²Celgene Corporation, Summit, NJ, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Oligoarticular disease in patients with psoriatic arthritis (PsA) is often underdiagnosed and undertreated. The goal of this study is to understand and identify current…
Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Christopher Collins ¹, Gail Kerr ², Joan Von Feldt ³, Bernie Rubin ⁴, Arie Katz ³, Vanessa Castellano ⁵, Jake Chung ⁴ and Christopher Bell⁵, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²Washington DC VA Medical Center, Georgetown and Howard Universities, Washington DC, DC, ³GSK, Philadelphia, PA, ⁴GSK, Phildelphia, PA, ⁵GSK, Research Triangle Park, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…
Abstract Number: 2720 • 2019 ACR/ARP Annual Meeting
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Rebecca Overbury¹, John Bohnsack ², CJ Inman ³, Sara Stern ³, Karen James ³, Daniel Clegg ³, Tracy Frech ⁴ and Aimee Hersh ³, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah School of Medicine, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…
Abstract Number: 2796 • 2019 ACR/ARP Annual Meeting
The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort
Adel Andemeskel¹, Vivi Feathers ¹, Christine Iannaccone ¹, Jing Cui ¹ and Nancy Shadick ¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Omega-3 supplementation is one of a few complementary and alternative medicine (CAM) therapies that has shown promise in improving RA symptoms through small, randomized…
Abstract Number: 2760 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Sebastian H. Unizony¹, Jinglan Pei², Páris N. Sidiropoulos², Jennie H. Best², Christine Birchwood² and John H. Stone³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, CA, ³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Previously, the GiACTA study demonstrated the superiority of subcutaneous (SC) tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in…
Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Judit Font Urgelles¹, Luis Rodriguez-Rodriguez², Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Leticia Leon², Inmaculada Morado¹, Esperanza Pato Cour¹, Juan A Jover Jover¹, Benjamín Fernández-Gutiérrez¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Brian C. Sauer¹, Chia-Chen Teng, MS¹, Neil A. Accortt², David H. Collier², Tzu-Chieh Lin² and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…
Abstract Number: 524 • 2018 ACR/ARHP Annual Meeting
Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice
Cristina Vadillo Font¹, María A Nieto², Dalifer Freites Núñez³, Zulema Rosales Rosado^1,3, Leticia Leon³, Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar³, ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Chest diseases, Hospital Clínico San Carlos, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the extra-articular manifestation that most frequently worsens the course of Rheumatoid arthritis (RA) disease. Purpose: To describe the characteristics…
Abstract Number: 2872 • 2018 ACR/ARHP Annual Meeting
Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
Anna O'Connor¹, Joshua Baker², Bryant R. England³, Brian C. Sauer⁴, Grant W. Cannon⁵ and J. Steuart Richards⁶, ¹Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁶Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The identification of risk factors associated with flares in RA is challenging because of the use of different composite disease activity scores and a…
Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Shintaro Hirata¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Katsuhiro Oi¹, Yusuke Yoshida¹, Tomohiro Sugimoto¹, Keisuke Oda^1,2, Takaki Nojima^1,3 and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].